We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Myhealthchecked Plc | LSE:MHC | London | Ordinary Share | GB00BN7K5L93 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.25 | -2.27% | 10.75 | 2,512 | 11:00:15 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10.50 | 11.00 | 11.00 | 10.75 | 11.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 10.98M | -159k | -0.0031 | -34.68 | 5.72M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:07:46 | O | 2,446 | 10.565 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/11/2024 | 10:11 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 01/10/2024 | 10:12 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 26/9/2024 | 14:04 | ALNC |  EARNINGS AND TRADING: Touchstar mulls strategic options as profit down |
| 26/9/2024 | 06:00 | UK RNS | MyHealthChecked PLC Half-year Report |
| 24/9/2024 | 09:47 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 20/9/2024 | 10:21 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 12/9/2024 | 06:00 | UK RNS | MyHealthChecked PLC Notice of Results |
| 28/6/2024 | 09:54 | UK RNS | MyHealthChecked PLC Result of AGM |
| 04/6/2024 | 15:41 | ALNC | EARNINGS AND TRADING: Hummingbird loss narrows as revenue climbs |
| 04/6/2024 | 06:00 | UK RNS | MyHealthChecked PLC Final Results & Notice of AGM |
Myhealthchecked (MHC) Share Charts1 Year Myhealthchecked Chart |
|
1 Month Myhealthchecked Chart |
Intraday Myhealthchecked Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 19/12/2024 | 15:53 | MyHealthChecked PLC to 100p | 10,254 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 21/12/2024 08:20 by Myhealthchecked Daily Update Myhealthchecked Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker MHC. The last closing price for Myhealthchecked was 11p.Myhealthchecked currently has 52,005,932 shares in issue. The market capitalisation of Myhealthchecked is £5,590,638. Myhealthchecked has a price to earnings ratio (PE ratio) of -34.68. This morning MHC shares opened at 11p |
Posted at 18/12/2024 13:07 by tia01 ControlMany companies that employ large numbers of people are suffering since the new government took over with minimum wage and employees NI rise. This won’t be a big issue for MHC because we don’t have a large number of staff and minimum wage wouldn’t be. Concern. What’s key is 100% the news regarding VAT and news on phlebotomy testing. We need clarity on revenue streams as we move away from Covid dependency revenue. I totally believe news is on the way but unfortunately I suspect in January at the earliest. Boots clearly believe in MHC and MHC in Boots. Would love a positive update on pharmacy2U deal and Poc doc launch due in January. More B2B deals also. Is this worth more than current value!. I believe it is 100% based on fundamentals. 1, cash position 2, No dilution 3, Boots deal and products 4, Digital data investment 5, regulatory approvals 6, Poc Doc deal 7, pharmacy 2U deal. 8, cost control 9 potential to add more tests like HIV test. Time for Penny to announce deal to allow Directors to buy |
Posted at 12/12/2024 12:20 by tia01 I personally can assure you Penny has positive plans. It’s all in the last statement from both Penny and Chairman. I do understand the comments but this is no dead duck. The future of health is in self testing. NHS is definitely in crisis. MHC could easily rocket, fall or do nothing but fact they have guided the company through 4 years since pandemic without raising or diluting is testimony to a prudent management team. Would I like to see more deals!for sure 100% but I’m equally sure one is in the pipeline between Boots and MHC regarding phlebotomy testing as in the Chairman’s statement. Is this a game changer. Absolutely because GPs are overwhelmed and this government wants to cut appointments which cost NHS £50 each. Digital data and self testing go hand in hand so hopefully 2025 will be MHCs year. An update due in January and expect news on this at some point. Inevitably as they move away from Covid testing it will be volatile however deals like the Poc Doc one and HIV tests are proving that MHC can see the direction for growth. Not to forget new online pharmacy deal. We also have a possible 1.6 VAT return coming so maybe MHC are waiting for 2025 to start motoring.More added stores do in store sales should rise over Christmas for new products!. Let’s wish the team well and follow Donald Hamilton as he keeps adding on weakness. |
Posted at 23/11/2024 12:02 by tia01 Penny appears to have got to grips with the manufacturing issues and the restocking in Boots is already underway. Recent price drop in share price is quite healthy as it’s enabled newbie’s to get in or LTHs to top up. I took advantage yesterday with a top up but who knows. I’m in for the long term and journey and if we get the phlebotomy testing deal over the line at Boots this could easily be a multi bagger imo. That’s the key for me as we move away from COVID revenue and we all know the NHS GP situation is getting worse so will Labour do the right thing to solve this by utilising Boots and MHC facilities!. Digital Data is the way forward and MHC is leading the charge so short term pain in pullbacks is long term gain in my eyes.Let’s hope for a little news during Christmas season. Good luck all and remember not many AIM companies still have cash to fund next phase as we do!. |
Posted at 27/10/2024 08:13 by tia01 DualWe know MHC has big plans and clearly in the middle of a deal that is game changing. It will clearly involve Boots and possibly government changes to pharmacy first products available to be used in stores with Boots specialists. The Poc Doc deal is significant also as it will also be sold over the counter or off the shelf. It’s all suggesting that one of the biggest killers in heart disease is a major focus so I personally see heart tests being added to the pharmacy first list. I could be wrong but the government know Boots with MHC tests and digital data can solve the GP appointment problems. Save costs and more efficient and save lives. MHC are focusing on LFT tests IMO which is why they ain’t restocked VITAMIN D tests as no margins in them. I also see a surprise and do wonder if Newfoundland may try a cheap takeover of MHC. They already supply the LFT tests and HIV tests to Boots via MHC!. They are also in many major shops but can’t get in Boots without MHC who have the required approval as you pointed out. Boots is extremely strict which is why it hasn’t stocked the prostrate tests because of the trauma it could cause after a positive test result etc. I think this may change as it’s a big issue. Chris Hoy a true ambassador and legend highlighting the need for more testing is testament to why Boots and MHC need to combine to offer a testing service to the public for NHS patients. Also note many black Caribbean suffer prostrate issues so Boots and MHC could use marketing to target the ethnic communities by highlighting this!. Anyway don’t expect and deal until the new year because of the parties involved and complexity involved. I do anticipate a market campaign to start in November to coincide with the run up to Christmas and the deal that will be announced in the new year hopefully. The focus on Covid revenue has clearly shifted towards testing and the question is can MHC get the revenue breaking deal done without a share dilution required!. I think the answer is 100 YES but equally a VAT refund will ensure the answer is yes. Also note Directors can’t buy until the deal is announced. Once again will Newfoundland be ambitious and smart enough to launch a strike for MHC knowing the potential benefits to both parties. Would MHC make a play for Newfoundland!!!! |
Posted at 26/9/2024 18:57 by tia01 I don’t know how low it goes but today’s sell off triggered a lot of negatives. Unless it bounces back tomorrow it could easily drift back to 12p or less. I’m positive about MHC longer term but the bears have been rampant today which is such a shame.I wish the news regarding boots had been delivered because we were so close to a breakout that could have seen us move towards 20s. The question is why Penny released results knowing they would impact share price without releasing details of the exciting news she proclaimed on LinkedIn in recently. That’s truly crazy because surely Boots and MHC given the relationship can agree terms to sign it off or does it involve a third party such as NHS deal!. Extremely bad timing for results however tomorrow will be interesting to see what happens after today |
Posted at 11/9/2024 18:02 by tia01 I seriously don’t think Penny believes there’s any money in LFT tests other than Covid ones.Fact is I’m Sure Newfoundland provide MHC with its LFT tests so I guess it’s hard for MHC to compete with them on those tests. MHC clearly focused on phlebotomy testing and I feel a deal with Boots to supply tests for NHS patients. GPs have made the government realise they need a new approach otherwise waiting lists will get even longer and waiting time also. I just feel the share price is suffering as a result of the wait for news. I don’t know what the value of Newfoundland is but could a Merger with MHC really make sense given one is focused more on LFT and the other phlebotomy tests. Time for Penny to deliver something really exciting to share so we can all go to the River Wye to celebrate lol. |
Posted at 29/8/2024 07:05 by tia01 Muck166So it looks like ABDX raised another 500k through share placement. 80%?take up but no Directors participation. Raised at decent share price with little to no discounts. It’s definitely an interesting market for MHC given MHC has self funded growth plan. If MHC can demonstrate growth in new products and a profit generating use for the digital data investment then this could easily re rate inline with ABDX. Crucial to see what’s said in update due. Need a deal with Boots to offer phlebotomy testing and possibly a an expansion of products offered on pharmacy first and we move up quickly. A lot to wish for but Penny must deliver as cash don’t last forever unless we have a plan for growth of new products |
Posted at 27/8/2024 11:32 by muck166 Tia - I don't want to get in a spat with you about valuations, especially on the MHC board. And I am not saying MHC is a bad company - it isn't.Yes, ABDX supplies Boots with some own label tests. In fact, they are exactly the same Chinese tests that MHC also sell through Boots, just in different packaging. And yes, ABDX makes and sells pregnancy tests, as well as other tests. But even a cursory look at its accounts will show you that revenue it makes from total product sales is less than 10% of its total revenue. The bulk of its revenue comes from CDMO/CRO activities on a fee for service model, ie it helps third party lateral flow developers move an idea to a commercial, approved LFT product that can be manufactured at scale and robustly. That is its main business, and its NOT the same as MHC. I don't know why MHC has an MCAP of less than ABDX, but if I were to guess I would say it's because MHC remains heavily reliant on COVID revenue (which is falling) and seems to be stagnating rather than growing, whereas ABDX has growing revenue from a multitude of different customers and streams, as well as some huge potential in its pipe. There are very good reasons why 3 institutional investors took almost all of the recent raise at less than a 10% discount - I assume it's because they see real growth potential in ABDX. Sadly, MHC isn't showing investors anything at the moment. |
Posted at 19/8/2024 13:07 by spacedust Mhc was valuable physically during the pandemic but as an investor this has been battered to the gutters. The share price was much higher without hardly any income.But now we have contracts galore with 1600% rise in profits the share price has declined very badly and there's no respite despite record breaking turnover |
Posted at 30/6/2024 08:52 by tia01 I took this morning to read the Chairman’s Statement and it’s clear a slowdown is expected in Covid tests in the first half of 2024.Is it all bad news! I personally see a slowdown that will see sales of Covid for first six months of 2024 to come in at around 3m based on 1 test being sold in each of the 1900 stores nationwide and also online sales during the period. You may think ouch but as stated in Chairman’s statement a decline is expected. The good thing is it’s evident the other tests provided by MHC will make up for lost revenue from the Covid tests as sales increase. I don’t expect a huge amount of revenue from new tests but it’s reasonable to expect between half a million and three quarters in the first half. So I would anticipate a similar overall figure to the first half in 2023 with combined sales and wellness tests. The key will be any update that may lead to an anticipated huge uptick in wellness test sales in Boots. We are expanding to another 200plus stores with wellness tests however this will come at a cost to MHC for the initial costs of shelving and stock etc. It will however add to the long term growth of revenue. It’s also self funded. I do expect strong cost control to reserve cash and also believe any collaboration with Boots pharmacy first and phlebotomy testing privately within Boots instore MOT services available could provide a catalyst needed. I don’t think a buy back will be announced although it would be a great idea. I believe the company will prioritise using cash for growing the business instead. I believe MHC should use Tik Tok content creators who advertise for free and at a cost of MHC sending a free sample to demonstrate. Of course MHC would need to sell the products on TIk Tok shop in order for content creators to access them and offer free promotions. TIk Tok viewers are probably between 16 to 40 but many of the tests are geared towards these ages and then we must remember that all these 18-40s have older family members they may buy a test for. Remember if you give a free test to 20 Tik Tok members who each have 20,000 plus followers for example that a potential sale to 400,000 off just 20 free samples! Times this by 50 free samples etc you see how quick it would be to get the brand out there for literally nothing. Then you have the benefits of being on TIK TOK shop. This would be great if they have a deal with Boots and use Tik Tok viewers to make people aware of the products and services etc. It would also help encourage direct sales to MHC and enhance the user rate of the digital data. MHC must be smart a use the 8m of cash wisely to gain traction to wellness tests which are the future of the business whilst Covid revenue is this available. Covid revenue is the key to growth without dilution and valuable for MHC. A recent surge in Covid cases will reflect in 2nd half results in my opinion as Boots will buy tests in advance based on the figures and projections to ensure they are stocked for winter 2024 and summer 2024. The market will only react to news flow from MHC which is expected imminently. Penny has a great opportunity to demonstrate the future of wellness testing combined with the importance of digital data which Poc Doc has demonstrated is the future |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
